Immunoflazid syrup 50 ml. Vial

Description

Immunoflazid Composition
1 ml of syrup contains:

0.02 ml of Proteflazid liquid extract obtained from a mixture of herbs (1: 1) Sod pike (Herba Deschampsia caespitosa L.) and Ground Veinik (Herba Calamagrostis epigeios L.) (extraction solvent – ethanol 96%), which is equivalent to at least 0 , 0035 mg of flavonoids calculated as rutin;
excipients: propylene glycol, ethanol 96%, sorbitol (E 420), methylparaben (E 218), propylparaben (E 216), sodium sulfite (E 221), purified water.

Immunoflazid Dosage form.

Syrup.

Basic physical and chemical properties: transparent sweet liquid of yellow-green color with a weak specific odor.

Immunoflazid Pharmacotherapeutic group.

Direct-acting antiviral agents. ATX J05A X.

Immunostimulants.

ATX code L0ZA X.

Pharmacological properties.

Pharmacodynamics.

The flavonoids in the preparation have the ability to suppress the replication of DNA and RNA viruses both in vitro and in vivo. During preclinical and clinical studies, the inhibitory activity of the drug against influenza viruses and acute respiratory infections, herpes viruses was revealed.

It has been proven that the mechanism of direct antiviral action is to inhibit the synthesis of virus-specific enzymes – DNA and RNA polymerases, thymidine kinase, reverse transcriptase, neuraminidase and induction of endogenous interferon synthesis.

The drug protects the mucous membranes of the upper respiratory tract, normalizing the indices of local immunity (lactoferrin, sIgA and lysozyme).

During the research, it was found that the drug normalizes the synthesis of endogenous a- and g-interferons to a physiologically active level, which increases the body’s nonspecific resistance to viral and bacterial infections.

Clinical studies have shown that under conditions of daily intake of the drug, according to age-specific doses and regimens, there is no refractoriness of the immune system: there is no inhibition of the synthesis of a- and g-interferons. This property of the Immunoflazid® syrup helps to maintain the level of interferons sufficient for an adequate immune response of the body to an infectious agent. In turn, this makes it possible, if necessary, to use the drug for a long time.

The drug has antioxidant activity, inhibits the course of free radical processes, thereby preventing the accumulation of lipid peroxidation products, enhancing the antioxidant status of cells, reduces intoxication, promotes the recovery of the body after infection and adaptation to adverse environmental conditions.

The drug is a modulator of apoptosis: it enhances the effect of apoptosis-inducing factors, namely, activating caspase 9, which contributes to a faster elimination of cells affected by the virus and the primary prevention of chronic diseases against the background of latent viral infections.

Pharmacokinetics.

The active ingredients of the drug are rapidly absorbed from the digestive tract into the blood, reaching maximum concentrations within 20 minutes after administration (in vivo studies). According to the existing dynamics, the half-life of blood plasma is about 2.3 hours. Oral bioavailability is 80%. Excretion from the body is slow. The level of accumulation of active substances by blood cells is significantly higher than that of blood plasma. Appropriate concentrations of active substances ensure prolongation of the drug’s action in the body and accumulation in organs and tissues due to the release of blood cells from them. Such available pharmacokinetic dynamics of accumulation and release of active substances by blood cells necessitates two doses of the drug per day to achieve effective concentrations.

Clinical characteristics.

Indications

Etiotropic treatment and prevention of ARVI;
etiotropic treatment and prevention of influenza, including those caused by viruses of pandemic strains.

Contraindications
Hypersensitivity to the components of the drug. Peptic ulcer of the stomach or duodenum in the acute stage. Autoimmune diseases.

Interaction with other medicinal products and other types of interactions.

During clinical use, the possibility of combining Imunoflazid® syrup with antibiotics and antifungal drugs for the treatment of viral-bacterial and viral-fungal diseases was established. Negative manifestations due to interaction with other drugs have not been established.